Unaudited consolidated and standalone Financial Results for quarter ended June 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 28 Jul 2026, 08:03 PM IST · BSE ID: bb02b62f-bd0d-412e-b0a2-8816b4472894
View Original BSE Filing (PDF)
💡
In Simple Terms
RPG Life Sciences reported higher Q1 FY27 earnings, with standalone profit up to Rs. 3,057 Lakhs.
🤖 AI Summary
- RPG Life Sciences Board approved unaudited standalone financial results for the quarter ended June 30, 2026.
- Standalone revenue from operations for Q1 FY27 was Rs. 19,569 Lakhs, up from Rs. 16,892 Lakhs YoY.
- Standalone profit for the period for Q1 FY27 reached Rs. 3,057 Lakhs, compared to Rs. 2,629 Lakhs YoY.
- Consolidated revenue from operations for Q1 FY27 stood at Rs. 19,569 Lakhs, with profit for the period at Rs. 3,061 Lakhs.
- The company operates solely within the Pharmaceuticals business segment.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q1 FY27)
19,569 Lakhs
15.85
Standalone Profit for the Period (Q1 FY27)
3,057 Lakhs
16.20
Consolidated Revenue from Operations (Q1 FY27)
19,569 Lakhs
15.85
Consolidated Profit for the Period (Q1 FY27)
3,061 Lakhs
16.47
Standalone Basic EPS (Q1 FY27)
18.49 Rs.
16.29
🏢 How This Affects the Company
The increase in revenue from operations indicates growth in the company's core Pharmaceuticals segment. This strengthens its market presence in its sole operational area.
Higher profit for the period contributes to improved earnings. The increase in total income from Rs. 17,415 Lakhs to Rs. 19,985 Lakhs standalone reflects enhanced financial performance.
The company continues its operations within a single business segment, Pharmaceuticals, indicating no significant shift in operational structure for the reported quarter.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, specifically the increase in standalone profit to Rs. 3,057 Lakhs and revenue from operations to Rs. 19,569 Lakhs for Q1 FY27.
🔍
Management Signal
The approval of these unaudited financial results signals management's focus on operational execution and profitability in the Pharmaceuticals segment.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Next quarterly results — observe revenue and profit growth trend.
Update on API division transfer to RPG Active Pharma Limited.
Monitoring of any further impact from New Labour Codes.
LOW RISK
No new specific risks were highlighted in the financial results.
💡 Investor Takeaway
RPG Life Sciences reported a standalone profit for the period of Rs. 3,057 Lakhs in Q1 FY27, an increase from Rs. 2,629 Lakhs in Q1 FY26. Standalone revenue from operations grew to Rs. 19,569 Lakhs from Rs. 16,892 Lakhs year-over-year.
⚖️ Strengths & Concerns
✅ Positives
- Standalone revenue from operations increased to Rs. 19,569 Lakhs in Q1 FY27 from Rs. 16,892 Lakhs in Q1 FY26.
- Standalone profit for the period rose to Rs. 3,057 Lakhs in Q1 FY27 from Rs. 2,629 Lakhs in Q1 FY26.
📅 Company Track Record
RPG Life Sciences previously announced a standalone profit of Rs. 3,057 Lakhs for Q1 FY27. The company's Board also approved FY26 results and recommended a Rs. 24/- dividend per share (300% of face value) on April 29, 2026. Prior Q1 FY26 standalone profit was Rs. 2,629 Lakhs.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was RPG Life Sciences' standalone revenue from operations in Q1 FY27?
RPG Life Sciences reported standalone revenue from operations of Rs. 19,569 Lakhs for the quarter ended June 30, 2026.
What was RPG Life Sciences' standalone profit for the period in Q1 FY27?
The standalone profit for the period for RPG Life Sciences was Rs. 3,057 Lakhs for the quarter ended June 30, 2026.
What was RPG Life Sciences' consolidated profit for the period in Q1 FY27?
RPG Life Sciences reported a consolidated profit for the period of Rs. 3,061 Lakhs for the quarter ended June 30, 2026.
What was RPG Life Sciences' standalone basic earnings per share (EPS) in Q1 FY27?
The standalone basic earnings per share for RPG Life Sciences was Rs. 18.49 for the quarter ended June 30, 2026.
In which business segment does RPG Life Sciences operate?
RPG Life Sciences operates in only one reportable business segment, which is Pharmaceuticals.
Questions based on this BSE filing only. For information purposes.